+

WO1996036330A3 - Compositions containing fatty acids for improving digestion and absorption in the small intestine - Google Patents

Compositions containing fatty acids for improving digestion and absorption in the small intestine Download PDF

Info

Publication number
WO1996036330A3
WO1996036330A3 PCT/US1996/007165 US9607165W WO9636330A3 WO 1996036330 A3 WO1996036330 A3 WO 1996036330A3 US 9607165 W US9607165 W US 9607165W WO 9636330 A3 WO9636330 A3 WO 9636330A3
Authority
WO
WIPO (PCT)
Prior art keywords
absorption
small intestine
fatty acids
compositions containing
containing fatty
Prior art date
Application number
PCT/US1996/007165
Other languages
French (fr)
Other versions
WO1996036330A2 (en
Inventor
Henry C Lin
Original Assignee
Cedars Sinai Medical Center
Henry C Lin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Henry C Lin filed Critical Cedars Sinai Medical Center
Priority to JP8535091A priority Critical patent/JPH11505258A/en
Priority to BR9608795A priority patent/BR9608795A/en
Priority to AU58629/96A priority patent/AU722133C/en
Priority to EP96920275A priority patent/EP0827402A2/en
Publication of WO1996036330A2 publication Critical patent/WO1996036330A2/en
Publication of WO1996036330A3 publication Critical patent/WO1996036330A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and compositions for slowing gastrointestinal transit and prolonging residence time, thereby optimizing presentation and absorption of ingested nutrients and/or pharmacologically active agents in the small intestine. The present invention further provides methods and compositions for enhancing the bioavailability and therapeutic effectiveness of pharmacologically active agents.
PCT/US1996/007165 1995-05-17 1996-05-16 Compositions containing fatty acids for improving digestion and absorption in the small intestine WO1996036330A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP8535091A JPH11505258A (en) 1995-05-17 1996-05-16 Compositions comprising fatty acids that improve digestion and absorption in the small intestine
BR9608795A BR9608795A (en) 1995-05-17 1996-05-16 Compositions containing fatty acids to improve digestion and absorption in the small intestine
AU58629/96A AU722133C (en) 1995-05-17 1996-05-16 Compositions containing fatty acids for improving digestion and absorption in the small intestine
EP96920275A EP0827402A2 (en) 1995-05-17 1996-05-16 Compositions containing fatty acids for improving digestion and absorption in the small intestine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44284395A 1995-05-17 1995-05-17
US42284395A 1995-05-17 1995-05-17
US08/442,843 1995-05-17

Publications (2)

Publication Number Publication Date
WO1996036330A2 WO1996036330A2 (en) 1996-11-21
WO1996036330A3 true WO1996036330A3 (en) 1997-05-22

Family

ID=27025783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/007165 WO1996036330A2 (en) 1995-05-17 1996-05-16 Compositions containing fatty acids for improving digestion and absorption in the small intestine

Country Status (1)

Country Link
WO (1) WO1996036330A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO1997005863A1 (en) * 1995-08-07 1997-02-20 Suntory Limited Preventive or remedy for diseases caused by abnormalities in cartilage tissues
AU759018B2 (en) * 1997-10-03 2003-04-03 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
DE10006836B4 (en) * 2000-04-18 2005-03-24 Bitec Gmbh Use of omega-3 fatty acids and / or compounds of omega-3 fatty acids
AU2001252559B2 (en) * 2000-05-02 2005-09-15 Otsuka Pharmaceutical Co., Ltd. Preparations for evaluating eliminative ability of stomach
RU2429883C2 (en) 2005-07-25 2011-09-27 Оцука Фармасьютикал Ко., Лтд. Oral composition effective for assessment of ability to metabolise pyridine
EP2498628B1 (en) 2010-12-29 2014-04-30 Abbott Laboratories Products for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
ES2813868T3 (en) 2012-08-20 2021-03-25 Otsuka Pharma Co Ltd Composition for use in a method of measuring carbohydrate metabolism capacity
KR20150132301A (en) 2013-03-15 2015-11-25 오츠카 세이야쿠 가부시키가이샤 Method of measuring insulin resistance with fatty acid combustion, and composition used herein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200902A2 (en) * 1985-03-26 1986-11-12 Fujisawa Pharmaceutical Co., Ltd. Drug carrier and pharmaceutical preparation comprising it
EP0539319A2 (en) * 1991-06-27 1993-04-28 Sandoz Ltd. Pharmaceutical cyclosporin composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200902A2 (en) * 1985-03-26 1986-11-12 Fujisawa Pharmaceutical Co., Ltd. Drug carrier and pharmaceutical preparation comprising it
EP0539319A2 (en) * 1991-06-27 1993-04-28 Sandoz Ltd. Pharmaceutical cyclosporin composition

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BROWN NJ ET AL: "Characteristics of lipid substances activating the ileal brake in the rat.", GUT, OCT 1990, 31 (10) P1126-9, ENGLAND, XP000613253 *
DREZNIK Z ET AL: "Effect of ileal oleate on interdigestive intestinal motility of the dog.", DIG DIS SCI, JUL 1994, 39 (7) P1511-8, UNITED STATES, XP000613256 *
HUGE, A. ET AL: "Effects of enteral feedback inhibition on motility, luminal flow, and absorption of nutrients in proximal gut of minipigs", DIGESTIVE DISEASES AND SCIENCES, vol. 40, no. 5, May 1995 (1995-05-01), pages 1024 - 34, XP000613720 *
LIN, H.C. ET AL: "Jejunal brake inhibition of small intestinal transit by fat in the proximal small intestine", DIGESTIVE DISEASES AND SCIENCES, vol. 41, no. 2, February 1996 (1996-02-01), pages 326 - 329, XP000613235 *
OHTANI N ET AL: "Mediators for ileal brake differ between the stomach and small intestine in conscious dogs", GASTROENTEROLOGY, 108 (4 SUPPL.). 1995. A660., XP000613262 *
PIRONI L ET AL: "Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY.", GASTROENTEROLOGY, SEP 1993, 105 (3) P733-9, UNITED STATES, XP000613255 *
READ, N.W. ET AL: "Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucan", GASTROENTEROLOGY, vol. 86, no. 2, 1984, pages 274 - 280, XP000613231 *
SAUNDERS DR ET AL: "Absorption of triglyceride by human small intestine: dose-response relationships.", AM J CLIN NUTR, OCT 1988, 48 (4) P988-91, UNITED STATES, XP000613273 *
SIEGLE ML ET AL: "Effects of ileal infusions of nutrients on motor patterns of canine small intestine.", AM J PHYSIOL, JUL 1990, 259 (1 PT 1) PG78-85, UNITED STATES, XP000613360 *
SOPER NJ ET AL: "The 'ileal brake' after ileal pouch-anal anastomosis.", GASTROENTEROLOGY, JAN 1990, 98 (1) P111-6, UNITED STATES, XP000613254 *
SPILLER, R.C. ET AL: "Further characterization of the "ileal brake" reflex in man-effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucan, and peptide YY", GUT, vol. 29, no. 8, 1988, pages 1942 - 1051, XP000613225 *
SPILLER, R.C. ET AL: "The ileal brake- inhibition of jejunal motility after ileal fat perfusion in man", GUT, vol. 25, no. 4, 1984, pages 365 - 374, XP000613230 *
ZHOU, X.T. ET AL: "Fat in distal gut inhibits intestinal transit more potently than fat in proximal gut", GASTROENTEROLOGY, vol. 108, no. 4, April 1995 (1995-04-01), pages A714, XP000613263 *

Also Published As

Publication number Publication date
WO1996036330A2 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
MX9708858A (en) Compositions containing fatty acids for improving digestion and absorption in the small intestine.
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
ZA200200259B (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents.
CA2274596A1 (en) Compositions and methods for enhancing intestinal function
RU94028653A (en) Pharmaceutical preparation
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
EP1045636A4 (en) Pharmaceutical compositions and methods for the treatment of failing myocardial tissue
CA2341973A1 (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
SI1509232T1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
CA2159058A1 (en) Inhibition of helicobacter
AU2470299A (en) Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
DE69624354D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF PROTEINASE AND A MONOGLYCERIDE
CA2270177A1 (en) Transdermal administration of ment
WO1996036330A3 (en) Compositions containing fatty acids for improving digestion and absorption in the small intestine
CA2253130A1 (en) A medicament for treating obesity and improving lipid metabolism
TW325996B (en) Anti-atherosclerotic composition containing 17α-dihydroequilin
GB9515279D0 (en) Improved therapeutic agents
CA2201855A1 (en) Preventive or remedy for diseases caused by abnormalities in cartilage tissues
CA2301267A1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
EP0194794A3 (en) Saccharide digestion inhibiting composition
AU6849198A (en) Neurotrypsin
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

ENP Entry into the national phase

Ref document number: 2220451

Country of ref document: CA

Ref country code: CA

Ref document number: 2220451

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 535091

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970708210

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996920275

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996920275

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970708210

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1019970708210

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载